Name (Synonyms) | Correlation | |
---|---|---|
drug2233 | Serological analyses to be lead on a pre-existing biobank Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D001172 | Arthritis, Rheumatoid NIH | 0.38 |
D001168 | Arthritis NIH | 0.29 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001370 | Rheumatoid arthritis HPO | 0.38 |
HP:0001369 | Arthritis HPO | 0.29 |
There is one clinical trial.
The FDA has approved the CipherOx CRI T1 Tablet for use in subjects aged 19-36, and that this study aims to evaluate the device in subjects aged outside of this range and is being used off label. The FDA determined the Cipher OX CRI T1 Tablet to be a class II device in 2016, and additional research has been done since the FDA determination to further support the use of the device outside of its current labeling.
Description: Volume of IV fluid infused during treatment
Measure: Volume of IV fluid infused Time: 1 yearDescription: Amount of blood pressure medication utilized during treatment
Measure: Quantity of Blood pressure medication administered Time: 1 yearDescription: Categorical determination of resuscitation status as over- or under- resuscitated
Measure: Resuscitation status Time: 1 yearDescription: FiO2 levels administered
Measure: FiO2 needs Time: 1 yearDescription: Days spent on oxygen
Measure: Days on Oxygen Time: 1 yearDescription: Number of participants with hospital acquired pneumonia
Measure: Number of participants with hospital acquired pneumonia Time: 1 yearDescription: Number of patients who acquire an acute kidney injury
Measure: Number of Patients with Acute Kidney Injury (AKI) Time: 1 yearDescription: Number of patients who experience hemodynamic collapse defined as drop in systolic blood pressure below 80mm Hg
Measure: Number of patients with hemodynamic collapse Time: 1 yearDescription: Number of patients who experience mortality
Measure: mortality Time: 1 year